Warning Letter — K.C. Pharmaceuticals, Inc.
The FDA issued a Warning Letter to K.C. Pharmaceuticals, Inc. following an inspection by the Center for Drug Evaluation and Research (CDER).
K.C. Pharmaceuticals, Inc. and personnel responsible for drug manufacturing, quality control, and regulatory compliance at the facility.
A Warning Letter from CDER signifies that the FDA has identified significant violations of cGMP regulations. This may lead to regulatory actions such as the withholding of product approvals or import alerts if the cited deficiencies are not adequately addressed. The source does not specify the exact nature of the violations, but typically these letters necessitate rigorous remediation of quality systems.
Conduct a comprehensive review of manufacturing records and quality systems to ensure alignment with current Good Manufacturing Practice (cGMP) standards. Evaluate existing corrective and preventive action (CAPA) plans to address any identified deficiencies in production or quality control.
FDA Warning Letter issued to: K.C. Pharmaceuticals, Inc.. 08/12/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kc-pharmaceuticals-inc-729870-08122026
Open in openFDA / FDA.gov